Talphera (TLPH) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	25821 Industrial Boulevard, Suite 400
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		119,318,584

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 13,271	$ 27,274	[1]
Short-term investments	35,428	15,612	[1]
Accounts receivable, net	153	635	[1]
Inventories, net	1,556	1,626	[1]
Prepaid expenses and other current assets	1,345	1,683	[1]
Total current assets	51,753	46,830	[1]
Operating lease right-of-use assets	4,454	3,150	[1]
Property and equipment, net	15,775	15,659	[1]
Other assets	281	656	[1]
Total Assets	72,263	66,295	[1]
Current Liabilities:
Accounts payable	2,228	2,737	[1]
Accrued and other liabilities	5,333	5,045	[1]
Long-term debt, current portion	8,780	8,735	[1]
Operating lease liabilities, current portion	729	1,118	[1]
Total current liabilities	17,070	17,635	[1]
Long-term debt, net of current portion	6,952	13,140	[1]
Deferred revenue	1,237	0
Operating lease liabilities, net of current portion	3,935	2,606	[1]
Liability related to the sale of future royalties, net of current portion	85,981	88,365	[1]
Other long-term liabilities	109	299	[1]
Total liabilities	115,284	122,045	[1]
Commitments and Contingencies
Stockholders’ Deficit:
Common stock, $0.001 par value—200,000,000 shares authorized as of September 30, 2021 and December 31, 2020; 119,317,335 and 98,812,008 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	119	98	[1]
Additional paid-in capital	422,527	382,637	[1]
Accumulated deficit	(465,667)	(438,485)	[1]
Total stockholders’ deficit	(43,021)	(55,750)	[1]
Total Liabilities and Stockholders’ Deficit	$ 72,263	$ 66,295	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	119,317,335	98,812,008
Common stock, shares outstanding (in shares)	119,317,335	98,812,008

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Revenue	$ 1,862	$ 1,368	$ 2,816	$ 4,678
Operating costs and expenses:
Cost of goods sold	439	1,851	2,519	4,732
Research and development	1,416	956	3,109	3,181
Selling, general and administrative	8,640	7,598	24,978	28,484
Total operating costs and expenses	10,495	10,405	30,606	36,397
Loss from operations	(8,633)	(9,037)	(27,790)	(31,719)
Other income:
Interest expense	(538)	(824)	(1,824)	(2,551)
Interest income and other income, net	32	106	92	311
Non-cash interest income on liability related to future sale of royalties	764	825	2,345	2,502
Total other income	258	107	613	262
Net loss before income taxes	(8,375)	(8,930)	(27,177)	(31,457)
Provision for income taxes	0	0	(5)	(4)
Net loss	(8,375)	(8,930)	(27,182)	(31,461)
Comprehensive loss	$ (8,375)	$ (8,930)	$ (27,182)	$ (31,461)
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.07)	$ (0.10)	$ (0.23)	$ (0.38)
Shares used in computing net loss per share of common stock, basic and diluted – See Note 11 (in shares)	119,224,484	87,912,505	117,222,219	82,895,664
Product [Member]
Revenue:
Revenue	$ 160	$ 1,287	$ 1,003	$ 1,864
Contract and Other Collaboration [Member]
Revenue:
Revenue	$ 1,702	$ 81	$ 1,813	$ 2,814

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	79,573,101
Balance at Dec. 31, 2019	$ 79	$ 356,609	$ (398,106)	$ (41,418)
Stock-based compensation		1,146		1,146
Restricted stock units vested (in shares)	216,399
Tax payments related to shares withheld for restricted stock units vested		(86)		(86)
Net proceeds from issuance of common stock in connection with equity financings (in shares)	431,800
Net proceeds from issuance of common stock in connection with equity financings	$ 1	783		784
Issuance of common stock upon ESPP purchase (in shares)	194,451
Issuance of common stock upon ESPP purchase		218		218
Net loss			(15,925)	(15,925)
Stock-based compensation		1,146		1,146
Restricted stock units vested (in shares)	216,399
Balance (in shares) at Mar. 31, 2020	80,415,751
Balance at Mar. 31, 2020	$ 80	358,670	(414,031)	(55,281)
Balance (in shares) at Dec. 31, 2019	79,573,101
Balance at Dec. 31, 2019	$ 79	356,609	(398,106)	(41,418)
Net loss				(31,461)
Balance (in shares) at Sep. 30, 2020	90,477,613
Balance at Sep. 30, 2020	$ 90	371,624	(429,567)	(57,853)
Balance (in shares) at Mar. 31, 2020	80,415,751
Balance at Mar. 31, 2020	$ 80	358,670	(414,031)	(55,281)
Stock-based compensation		1,090		1,090
Restricted stock units vested (in shares)	29,434
Net proceeds from issuance of common stock in connection with equity financings (in shares)	445,000
Net proceeds from issuance of common stock in connection with equity financings		665		665
Net loss			(6,606)	(6,606)
Stock-based compensation		1,090		1,090
Restricted stock units vested (in shares)	29,434
Balance (in shares) at Jun. 30, 2020	80,890,185
Balance at Jun. 30, 2020	$ 80	360,425	(420,637)	(60,132)
Stock-based compensation	$ 0	1,104	0	1,104
Restricted stock units vested (in shares)	7,789
Net proceeds from issuance of common stock in connection with equity financings (in shares)	9,433,962
Net proceeds from issuance of common stock in connection with equity financings	$ 10	9,941	0	9,951
Issuance of common stock upon ESPP purchase (in shares)	145,677
Issuance of common stock upon ESPP purchase	$ 0	154	0	154
Net loss	0	0	(8,930)	(8,930)
Stock-based compensation	$ 0	1,104	0	1,104
Restricted stock units vested (in shares)	7,789
Balance (in shares) at Sep. 30, 2020	90,477,613
Balance at Sep. 30, 2020	$ 90	371,624	(429,567)	(57,853)
Balance (in shares) at Dec. 31, 2020	98,812,008
Balance at Dec. 31, 2020	$ 98	382,637	(438,485)	(55,750)	[1]
Stock-based compensation		1,089		1,089
Restricted stock units vested (in shares)	404,172
Tax payments related to shares withheld for restricted stock units vested		(249)		(249)
Net proceeds from issuance of common stock in connection with equity financings (in shares)	19,701,562
Net proceeds from issuance of common stock in connection with equity financings	$ 20	36,340		36,360
Issuance of common stock upon ESPP purchase (in shares)	183,132
Issuance of common stock upon ESPP purchase		192		192
Issuance of common stock upon exercise of stock options (in shares)	2,125
Issuance of common stock upon exercise of stock options		2		2
Net loss			(8,956)	(8,956)
Stock-based compensation		1,089		1,089
Restricted stock units vested (in shares)	404,172
Balance (in shares) at Mar. 31, 2021	119,102,999
Balance at Mar. 31, 2021	$ 118	420,011	(447,441)	(27,312)
Balance (in shares) at Dec. 31, 2020	98,812,008
Balance at Dec. 31, 2020	$ 98	382,637	(438,485)	(55,750)	[1]
Net loss				(27,182)
Balance (in shares) at Sep. 30, 2021	119,317,335
Balance at Sep. 30, 2021	$ 119	422,527	(465,667)	(43,021)
Balance (in shares) at Mar. 31, 2021	119,102,999
Balance at Mar. 31, 2021	$ 118	420,011	(447,441)	(27,312)
Stock-based compensation		1,172		1,172
Restricted stock units vested (in shares)	74,438
Issuance of common stock upon exercise of stock options (in shares)	2,369
Issuance of common stock upon exercise of stock options	$ 1	1		2
Net loss			(9,851)	(9,851)
Restricted stock units vested	$ 0	0	0	0
Stock-based compensation		1,172		1,172
Restricted stock units vested (in shares)	74,438
Balance (in shares) at Jun. 30, 2021	119,179,806
Balance at Jun. 30, 2021	$ 119	421,184	(457,292)	(35,989)
Stock-based compensation	$ 0	1,221	0	1,221
Restricted stock units vested (in shares)	7,793
Issuance of common stock upon ESPP purchase (in shares)	114,827
Issuance of common stock upon ESPP purchase	$ 0	109	0	109
Issuance of common stock upon exercise of stock options (in shares)	14,909
Issuance of common stock upon exercise of stock options	$ 0	13	0	13
Net loss	0	0	(8,375)	(8,375)
Stock-based compensation	$ 0	1,221	0	1,221
Restricted stock units vested (in shares)	7,793
Balance (in shares) at Sep. 30, 2021	119,317,335
Balance at Sep. 30, 2021	$ 119	$ 422,527	$ (465,667)	$ (43,021)
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		72 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (8,375)	$ (8,956)	$ (8,930)	$ (15,925)	$ (27,182)	$ (31,461)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization					(83)	(181)
Non-cash interest income on liability related to future sale of royalties	(764)		(825)		(2,345)	(2,502)	$ 25,880
Depreciation and amortization					1,512	1,471
Non-cash interest expense related to debt financing					607	823
Stock-based compensation					3,482	3,340
Other					89	463
Changes in operating assets and liabilities:
Accounts receivable					482	(696)
Inventories					(180)	734
Prepaid expenses and other assets					320	616
Accounts payable					281	174
Accrued liabilities					390	(1,238)
Operating lease liabilities					(559)	(673)
Deferred revenue					1,188	(3,048)
Net cash used in operating activities					(21,998)	(32,178)
Cash flows from investing activities:
Purchase of property and equipment					(1,799)	(224)
Purchase of investments					(53,869)	(38,817)
Proceeds from sales and maturities of investments					33,984	67,405
Net cash (used in) provided by investing activities					(21,684)	28,364
Cash flows from financing activities:
Payment of long-term debt					(6,750)	(2,583)
Net proceeds from issuance of common stock in connection with equity financings					36,360	11,400
Net proceeds from issuance of common stock through equity plans					318	372
Payment of employee tax obligations related to vesting of restricted stock units					(249)	(86)
Net cash provided by financing activities					29,679	9,103
Net (decrease) increase in cash and cash equivalents					(14,003)	5,289
Cash and cash equivalents—Beginning of period		$ 27,274		$ 14,684	27,274	14,684
Cash and cash equivalents—End of period	$ 13,271		$ 19,973		$ 13,271	$ 19,973	$ 13,271

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. The Company AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 January 2006, AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one July 2021, Out-License Agreement (DZUVEO) May 12, 2021 ( Termination of Gr nenthal Agreements July 2021, 10 3 10 50 In-License Agreement November 14, 2021, Acquisition The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of September 30, 2021 December 31, 2020, one 10 September 18, 2015, August 31, 2020, third DSUVIA/DZUVEO DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 June 2018, DSUVIA was approved with a Risk Evaluation and Mitigation Strategy, or REMS, program which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified under the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not Zalviso Zalviso delivers 15 September 2013 July 25, 2014. IAP312, IAP312 August 2017, three 3 Termination of Gr ü nenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021. Out-License Agreement (DZUVEO) On July 14, 2021, The DZUVEO Agreement has an initial term of ten 10 first December 31 December 31, 2022, January 1, 2022 April 30, 2022). five not six 6 may not The Company is entitled to receive up to €47.0 €2.5 third 2021, third 2021. Beginning in the third third The DZUVEO Agreement also provides Aguettant with a right of first eighteen 18 In-License Agreement On July 14, 2021, 10 3 10 50 The PFS Agreement has an initial term of ten 10 first December 31 first December 31 first January 1 April 30 five not six 6 Aguettant is entitled to receive up to $24.0 million in sales-based milestone payments. The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from 40% to 45% of net sales in the United States. The Company and Aguettant will agree on minimum sales obligations twelve 12 third As of September 30, 2021, no Acquisition On November 14, 2021, two fourth 2021 12 5. 10 Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note 7 Reclassifications Certain prior period amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current period's presentation. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and the rules and regulations of the SEC. Accordingly, they do not Operating results for the three nine September 30, 2021, not may December 31, 2021 December 31, 2020, December 31, 2020, 10 10 December 31, 2020, Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not Significant Accounting Policies The Company’s significant accounting policies are detailed in its Annual Report on Form 10 December 31, 2020. no three nine September 30, 2021, 2020 10 Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. not

Note 2 - Investments and Fair V

Note 2 - Investments and Fair Value Measurement	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Investments and Fair Value Measurement Disclosure [Text Block]	2. Investments The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond one The table below summarizes the Company’s cash, cash equivalents and short-term investments (in thousands): As of September 30, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 2,984 $ — $ — $ 2,984 Money market funds 10,287 — — 10,287 Total cash and cash equivalents 13,271 — — 13,271 Short-term investments: Commercial paper 25,913 — — 25,913 Corporate debt securities 9,515 — — 9,515 Total short-term investments 35,428 — — 35,428 Total cash, cash equivalents and short-term investments $ 48,699 $ — $ — $ 48,699 As of December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 5,181 $ — $ — $ 5,181 Money market funds 3,996 — — 3,996 Commercial paper 18,097 — — 18,097 Total cash and cash equivalents 27,274 — — 27,274 Short-term investments: U.S. government agency securities 5,818 — — 5,818 Commercial paper 9,794 — — 9,794 Total short-term investments 15,612 — — 15,612 Total cash, cash equivalents and short-term investments $ 42,886 $ — $ — $ 42,886 There were no other-than-temporary impairments for these securities at September 30, 2021 December 31, 2020. no three nine September 30, 2021 2020. As of September 30, 2021, December 31, 2020, one Fair Value Measurement The Company’s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds and U.S. treasury securities are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 third September 30, 2021, December 31, 2020, 5 two The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): As of September 30, 2021 Fair Value Level I Level II Level III Assets Money market funds $ 10,287 $ 10,287 $ — $ — Commercial paper 25,913 — 25,913 — Corporate debt securities 9,515 — 9,515 — Total assets measured at fair value $ 45,715 $ 10,287 $ 35,428 $ — Liabilities Contingent put option liability $ 109 $ — $ — $ 109 Total liabilities measured at fair value $ 109 $ — $ — $ 109 As of December 31, 2020 Fair Value Level I Level II Level III Assets Money market funds $ 3,996 $ 3,996 $ — $ — U.S. government agency securities 5,818 — 5,818 — Commercial paper 27,891 — 27,891 — Total assets measured at fair value $ 37,705 $ 3,996 $ 33,709 $ — Liabilities Contingent put option liability $ 246 $ — $ — $ 246 Total liabilities measured at fair value $ 246 $ — $ — $ 246 The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three nine September 30, 2021 2020 Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Fair value—beginning of period $ 128 $ 246 Change in fair value of contingent put option associated with the Loan Agreement (19 ) (137 ) Fair value—end of period $ 109 $ 109 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Fair value—beginning of period $ 591 $ 437 Change in fair value of contingent put option associated with the Loan Agreement (85 ) 69 Fair value—end of period $ 506 $ 506

Note 3 - Inventories, Net

Note 3 - Inventories, Net	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value and consist of the following (in thousands): Balance as of September 30, 2021 December 31, 2020 Raw materials $ 579 $ 257 Work-in-process 68 30 Finished goods 909 1,339 Total $ 1,556 $ 1,626 The Company recorded inventory impairment charges of $0.1 and $0.2 million for the three nine September 30, 2021, three nine September 30, 2020, nine September 30, 2020, may

Note 4 - Revenue From Contracts

Note 4 - Revenue From Contracts With Customers	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4. The following table summarizes revenue from contracts with customers for the three nine September 30, 2021 2020 Three months ended September 30, 2021 Nine months ended September 30, 2021 Product sales: DSUVIA $ 160 $ 733 Zalviso — 270 Total product sales 160 1,003 Contract and collaboration revenue: License revenue 1,696 1,696 Non-cash royalty revenue related to Royalty Monetization (Note 7) — 83 Royalty revenue — 28 Other revenue 6 6 Total revenues from contract and other collaboration 1,702 1,813 Total revenue $ 1,862 $ 2,816 Three months ended September 30, 2020 Nine months ended September 30, 2020 Product sales: DSUVIA $ 935 $ 1,092 Zalviso 352 772 Total product sales 1,287 1,864 Contract and collaboration revenue: Non-cash royalty revenue related to Royalty Monetization (Note 7) 60 181 Royalty revenue 21 61 Other revenue — 2,572 Total revenues from contract and other collaboration 81 2,814 Total revenue $ 1,368 $ 4,678 For additional details on the Company’s accounting policy regarding revenue recognition, refer to Note 1 10 December 31, 2020. Product Sales The Company’s commercial launch of DSUVIA in the United States occurred in the first 2019. May 12, 2021. not September 30, 2021. Contract and Other Collaboration Contract and other collaboration revenue includes revenue under the Grünenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe. The Company concluded that Aguettant is a customer and therefore revenue recognition for the DZUVEO Agreement in Europe should be accounted for in accordance with FASB Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers The Company identified the following promises under the DZUVEO Agreement at inception, namely: (a) granting of the licenses, (b) manufacturing services inclusive of quality control testing and stability testing which are options in the initial arrangement, and (c) a material right associated with the discounted price for future optional orders of DZUVEO commercial product supply. The licenses are considered to be functional intellectual property. The Company determined that the licenses are capable of being distinct because Aguettant can benefit from the license on its own by commercializing the underlying product using its own resources. The Company manufacturing services are not third no not The Company evaluated if there is an interdependence between the performance obligations and determined that the licenses are a combined solution and the predominant performance obligation. The material right is separately identifiable in the context of the contract and is not not not The transaction price at the inception of the DZUVEO Agreement consisted of the upfront fee of €2.5 September 30, 2021 no The Company determined that the $52.2 million not The transaction price is allocated to the performance obligations based on relative standalone selling price which were determined for the licenses using the adjusted market approach, and for the manufacturing services and the material right associated with discounted DZUVEO product supply using the cost-plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates. For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in July 2021 10 five Revenue for the granting of the licenses was recognized on the effective date of the DZUVEO Agreement at the point in time that the licenses are effective. The manufacturing services inclusive of quality control testing and stability testing will be recognized at a point in time when, or as, the Company transfers the associated promised goods and services to Aguettant. The material right for the discounted price per unit on future optional orders will be recognized over time with the measure of progress being straight-line over the period in which the Company stands ready to provide the discounted price per unit on the manufacturing services. For the three September 30, 2021, September 30, 2021, not no September 30, 2021 As of September 30, 2021, three nine September 30, 2021 $0.3 Contract Liabilities The following table presents changes in the Company’s contract liabilities for the nine September 30, 2021 ( Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liabilities: Deferred revenue – DZUVEO Agreement $ — $ 1,237 $ — $ 1,237 Deferred revenue – Grünenthal Agreements 49 — (49 ) — Deferred revenue $ 49 $ 1,237 $ (49 ) $ 1,237 For the three nine September 30, 2021 2020, Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ — $ 147 $ 49 $ 380 Performance obligations eliminated upon termination — — — 2,572 New activities in the period from performance obligations satisfied: Performance obligations satisfied at a point in time 1,696 205 1,917 392 Total revenue from performance obligations satisfied or eliminated $ 1,696 $ 352 $ 1,966 $ 3,344

Note 5 - Long-term Debt

Note 5 - Long-term Debt	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	5. Loan Agreement with Oxford On May 30, 2019, May 30, 2019. In connection with the Loan Agreement, on May 30, 2019, As of September 30, 2021 December 31, 2020, three nine September 30, 2021, three nine September 30, 2020, Non-Interest Bearing Payments for the Construction of Leasehold Improvements In August 2019, may four July 2022. September 30, 2021 December 31, 2020, September 30, 2021 December 31, 2020

Note 6 - Leases

Note 6 - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. Office Leases The Company leased office and laboratory space for its former corporate headquarters, located at 301 351 On March 26, 2021, April 30, 2021. nine September 30, 2021. April 30, 2021, nine September 30, 2021. On March 26, 2021, 25821 April 1, 2021. two three one Contract Manufacturing Leases On April 21, 2021, March 31, 2021, 30 The term of the CSA is for a period of five first two one 24 The Company will pay Catalent an annual fee of $1.0 million beginning January 1, 2022. 10 December 31, 2022, may January 1 January 1, 2023, The Company has determined that the fixed fees in the CSA are in-substance lease payments. The Company concluded that this agreement contains an embedded lease as the clean rooms have been built specifically for production of the Company’s product and their use is effectively controlled by the Company as it has sole use over the space during the term of the agreement. The Company accounts for the agreement as an operating lease and has evaluated the non-cancelable lease term to be through the binding commitment date of May 15, 2027. In addition, the Company has entered into an agreement for commercial supply manufacturing services related to the Company’s Zalviso drug product with a contract manufacturing organization, which it accounts for as an operating lease. The components of lease expense are presented in the following table (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating lease costs $ 343 $ 305 $ 1,123 $ 914 Gain on derecognition of operating lease — — (522 ) — Sublease income — (150 ) (199 ) (449 ) Loss on termination of sublease — — 331 — Net lease costs $ 343 $ 155 $ 733 $ 465 The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table: September 30, 2021 Weighted-average remaining term – operating lease (years) 5.21 Weighted-average discount rate – operating lease 12.80 % Future minimum lease payments as of September 30, 2021 Year: 2021 (remaining three months) $ 237 2022 1,483 2023 1,194 2024 1,040 2025 1,040 2026 1,040 Thereafter 415 Total future minimum lease payments 6,449 Less imputed interest (1,785 ) Total $ 4,664 Reported as: Operating lease liabilities $ 4,664 Operating lease liabilities, current portion (729 ) Operating lease liabilities, net of current portion $ 3,935

Note 7 - Liability Related to S

Note 7 - Liability Related to Sale of Future Royalties	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Liability Related To Sale Of Future Royalties Disclosure [Text Block]	7. On September 18, 2015, first four 80% The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. During the three June 30, 2020, November 13, 2020. May 12, 2021 May 12, 2021. may The effective interest rate over the life of the liability will be 0% as the Company records interest income over the remaining term of the arrangement as an offset to the interest expense that was recognized in prior periods. The effective interest income rate for each of the three nine September 30, 2021 2020, The following table shows the activity within the liability account for the nine September 18, 2015 September 30, 2021 ( Nine months ended September 30, 2021 Period from inception to September 30, 2021 Liability related to sale of future royalties — beginning balance $ 88,471 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue (145 ) (1,083 ) Non-cash interest (income) expense recognized (2,345 ) 25,880 Liability related to sale of future royalties as of September 30, 2021 $ 85,981 $ 85,981 As royalties are remitted to SWK from ARPI LLC, as described in Note 1 10 December 31, 2020,

Note 8 - Legal Proceedings

Note 8 - Legal Proceedings	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	8. On June 8, 2021, 10 20 10b 5 August 9, 2021 December 16, 2021. On July 6, 2021, September 30, 2021 October 26, 2021, two nine three first two not third Item 1A. Risks of a General Nature Litigation may The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Equity Common Stock Underwritten Public Offering On January 22, 2021, January 27, 2021, ATM Agreement The Company has entered into a Controlled Equity Offering SM may There were no shares of common stock sold pursuant to the ATM Agreement during the three September 30, 2021. nine September 30, 2021, no three September 30, 2020. nine September 30, 2020, September 30, 2021, may Amended Stock Plan Amended 2020 On June 17, 2021, 2021 2020 2020 2020 may 2020 not 2020 2020 2011 may 2020 2020

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. The Company recorded total stock-based compensation expense for stock options, stock awards and awards made under the Amended 2011 Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of goods sold $ 24 $ 25 $ 67 $ 98 Research and development 216 188 597 572 Selling, general and administrative 981 891 2,818 2,670 Total $ 1,221 $ 1,104 $ 3,482 $ 3,340 As of September 30, 2021,

Note 11 - Net Loss Per Share of

Note 11 - Net Loss Per Share of Common Stock	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	11. The Company’s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock as their effect is antidilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: September 30, 2021 2020 ESPP, RSUs and stock options to purchase common stock 16,475,322 14,669,512 Common stock warrants 176,679 176,679

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	12. Acquisition On November 14, 2021, two 1, 2, 1 2 2 Pursuant to the Merger Agreement, the Company will acquire Lowell in a transaction valued at approximately $32.5 million plus net cash acquired, and subject to certain other adjustments. The transaction value includes approximately $26.0 million of contingent consideration payable upon the achievement of regulatory and sales-based milestones. If the acquisition of Lowell is completed, an amount of shares of AcelRx common stock valued at approximately $6.5 million will be issued to Lowell securityholders at the closing, subject to the condition to closing that Lowell has at least $3.5 million in cash at the closing and assuming certain stockholders of Lowell elect to receive merger consideration up to $3.5 million payable in cash. If those stockholders do not fourth 2021, 5. 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Business Description of Entity [Policy Text Block]	The Company AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 January 2006, AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one July 2021, Out-License Agreement (DZUVEO) May 12, 2021 ( Termination of Gr nenthal Agreements July 2021, 10 3 10 50 In-License Agreement November 14, 2021, Acquisition The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of September 30, 2021 December 31, 2020, one 10 September 18, 2015, August 31, 2020, third DSUVIA/DZUVEO DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 June 2018, DSUVIA was approved with a Risk Evaluation and Mitigation Strategy, or REMS, program which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified under the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not Zalviso Zalviso delivers 15 September 2013 July 25, 2014. IAP312, IAP312 August 2017, three 3 Termination of Gr ü nenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021. Out-License Agreement (DZUVEO) On July 14, 2021, The DZUVEO Agreement has an initial term of ten 10 first December 31 December 31, 2022, January 1, 2022 April 30, 2022). five not six 6 may not The Company is entitled to receive up to €47.0 €2.5 third 2021, third 2021. Beginning in the third third The DZUVEO Agreement also provides Aguettant with a right of first eighteen 18 In-License Agreement On July 14, 2021, 10 3 10 50 The PFS Agreement has an initial term of ten 10 first December 31 first December 31 first January 1 April 30 five not six 6 Aguettant is entitled to receive up to $24.0 million in sales-based milestone payments. The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from 40% to 45% of net sales in the United States. The Company and Aguettant will agree on minimum sales obligations twelve 12 third As of September 30, 2021, no Acquisition On November 14, 2021, two fourth 2021 12 5. 10
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note 7
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior period amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current period's presentation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and the rules and regulations of the SEC. Accordingly, they do not Operating results for the three nine September 30, 2021, not may December 31, 2021 December 31, 2020, December 31, 2020, 10 10 December 31, 2020,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. not

Note 2 - Investments and Fair_2

Note 2 - Investments and Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of September 30, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 2,984 $ — $ — $ 2,984 Money market funds 10,287 — — 10,287 Total cash and cash equivalents 13,271 — — 13,271 Short-term investments: Commercial paper 25,913 — — 25,913 Corporate debt securities 9,515 — — 9,515 Total short-term investments 35,428 — — 35,428 Total cash, cash equivalents and short-term investments $ 48,699 $ — $ — $ 48,699 As of December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 5,181 $ — $ — $ 5,181 Money market funds 3,996 — — 3,996 Commercial paper 18,097 — — 18,097 Total cash and cash equivalents 27,274 — — 27,274 Short-term investments: U.S. government agency securities 5,818 — — 5,818 Commercial paper 9,794 — — 9,794 Total short-term investments 15,612 — — 15,612 Total cash, cash equivalents and short-term investments $ 42,886 $ — $ — $ 42,886
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	As of September 30, 2021 Fair Value Level I Level II Level III Assets Money market funds $ 10,287 $ 10,287 $ — $ — Commercial paper 25,913 — 25,913 — Corporate debt securities 9,515 — 9,515 — Total assets measured at fair value $ 45,715 $ 10,287 $ 35,428 $ — Liabilities Contingent put option liability $ 109 $ — $ — $ 109 Total liabilities measured at fair value $ 109 $ — $ — $ 109 As of December 31, 2020 Fair Value Level I Level II Level III Assets Money market funds $ 3,996 $ 3,996 $ — $ — U.S. government agency securities 5,818 — 5,818 — Commercial paper 27,891 — 27,891 — Total assets measured at fair value $ 37,705 $ 3,996 $ 33,709 $ — Liabilities Contingent put option liability $ 246 $ — $ — $ 246 Total liabilities measured at fair value $ 246 $ — $ — $ 246
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Fair value—beginning of period $ 128 $ 246 Change in fair value of contingent put option associated with the Loan Agreement (19 ) (137 ) Fair value—end of period $ 109 $ 109 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Fair value—beginning of period $ 591 $ 437 Change in fair value of contingent put option associated with the Loan Agreement (85 ) 69 Fair value—end of period $ 506 $ 506

Note 3 - Inventories, Net (Tabl

Note 3 - Inventories, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Balance as of September 30, 2021 December 31, 2020 Raw materials $ 579 $ 257 Work-in-process 68 30 Finished goods 909 1,339 Total $ 1,556 $ 1,626

Note 4 - Revenue From Contrac_2

Note 4 - Revenue From Contracts With Customers (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended September 30, 2021 Nine months ended September 30, 2021 Product sales: DSUVIA $ 160 $ 733 Zalviso — 270 Total product sales 160 1,003 Contract and collaboration revenue: License revenue 1,696 1,696 Non-cash royalty revenue related to Royalty Monetization (Note 7) — 83 Royalty revenue — 28 Other revenue 6 6 Total revenues from contract and other collaboration 1,702 1,813 Total revenue $ 1,862 $ 2,816 Three months ended September 30, 2020 Nine months ended September 30, 2020 Product sales: DSUVIA $ 935 $ 1,092 Zalviso 352 772 Total product sales 1,287 1,864 Contract and collaboration revenue: Non-cash royalty revenue related to Royalty Monetization (Note 7) 60 181 Royalty revenue 21 61 Other revenue — 2,572 Total revenues from contract and other collaboration 81 2,814 Total revenue $ 1,368 $ 4,678
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liabilities: Deferred revenue – DZUVEO Agreement $ — $ 1,237 $ — $ 1,237 Deferred revenue – Grünenthal Agreements 49 — (49 ) — Deferred revenue $ 49 $ 1,237 $ (49 ) $ 1,237 Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ — $ 147 $ 49 $ 380 Performance obligations eliminated upon termination — — — 2,572 New activities in the period from performance obligations satisfied: Performance obligations satisfied at a point in time 1,696 205 1,917 392 Total revenue from performance obligations satisfied or eliminated $ 1,696 $ 352 $ 1,966 $ 3,344

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating lease costs $ 343 $ 305 $ 1,123 $ 914 Gain on derecognition of operating lease — — (522 ) — Sublease income — (150 ) (199 ) (449 ) Loss on termination of sublease — — 331 — Net lease costs $ 343 $ 155 $ 733 $ 465 September 30, 2021 Weighted-average remaining term – operating lease (years) 5.21 Weighted-average discount rate – operating lease 12.80 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year: 2021 (remaining three months) $ 237 2022 1,483 2023 1,194 2024 1,040 2025 1,040 2026 1,040 Thereafter 415 Total future minimum lease payments 6,449 Less imputed interest (1,785 ) Total $ 4,664 Operating lease liabilities $ 4,664 Operating lease liabilities, current portion (729 ) Operating lease liabilities, net of current portion $ 3,935

Note 7 - Liability Related to_2

Note 7 - Liability Related to Sale of Future Royalties (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Other Liabilities [Table Text Block]	Nine months ended September 30, 2021 Period from inception to September 30, 2021 Liability related to sale of future royalties — beginning balance $ 88,471 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue (145 ) (1,083 ) Non-cash interest (income) expense recognized (2,345 ) 25,880 Liability related to sale of future royalties as of September 30, 2021 $ 85,981 $ 85,981

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of goods sold $ 24 $ 25 $ 67 $ 98 Research and development 216 188 597 572 Selling, general and administrative 981 891 2,818 2,670 Total $ 1,221 $ 1,104 $ 3,482 $ 3,340

Note 11 - Net Loss Per Share _2

Note 11 - Net Loss Per Share of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2021 2020 ESPP, RSUs and stock options to purchase common stock 16,475,322 14,669,512 Common stock warrants 176,679 176,679

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) $ in Thousands, € in Millions	Nov. 14, 2021USD ($)	Jul. 14, 2021USD ($)	Jul. 31, 2021	Sep. 30, 2021USD ($)	Sep. 30, 2021EUR (€)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Jul. 14, 2021EUR (€)	Dec. 31, 2020USD ($)
Cash, Cash Equivalents, and Short-term Investments, Total				$ 48,699			$ 48,699			$ 42,886
Revenue from Contract with Customer, Including Assessed Tax				1,862		$ 1,368	$ 2,816	$ 4,678
Lowell Therapeutics [Member] | Subsequent Event [Member]
Business Combination, Consideration Transferred, Net of Cash Acquired	$ 32,500
Aguettant [Member] | DZUVEO [Member]
License Agreement, Term (Year)		10 years	10 years
License Agreement, Renewal Term (Year)		5 years	5 years
License Agreement, Upfront and Maximum Milestone Payments to be Received | €									€ 47
Proceeds form Up-front and Sales-based Milestone License Payments				2,900	€ 2.5
Revenue from Contract with Customer, Including Assessed Tax				$ 1,700
Aguettant [Member] | DZUVEO [Member] | Minimum [Member]
License Agreement, Percent of Revenue Share Payments to be Received		35.00%
Aguettant [Member] | DZUVEO [Member] | Maximum [Member]
License Agreement, Percent of Revenue Share Payments to be Received		45.00%
Aguettant [Member] | PFS Products [Member]
License Agreement, Term (Year)		10 years
License Agreement, Renewal Term (Year)		5 years
License Agreement, Milestone Payments to be Paid, Maximum		$ 24,000
License Agreement, Minimum Sales Obligation Term (Month)		12 months
Aguettant [Member] | PFS Products [Member] | Minimum [Member]
License Agreement, Percent of Revenue Share Payment to be Paid		40.00%
Aguettant [Member] | PFS Products [Member] | Maximum [Member]
License Agreement, Percent of Revenue Share Payment to be Paid		45.00%

Note 2 - Investments and Fair_3

Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total			$ 0		$ 0
Debt Securities, Available-for-sale, Realized Gain (Loss), Total	$ 0	$ 0	$ 0	$ 0

Note 2 - Investments and Fair_4

Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Cash, amortized cost	$ 2,984	$ 5,181
Cash and cash equivalent, fair value	13,271	27,274
Money market funds, amortized cost	10,287	3,996
Cash and cash equivalents	13,271	27,274	[1]
Short-term investment, amortized Cost	35,428	15,612
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	35,428	15,612
Total cash, cash equivalents and short-term investments	48,699	42,886
Total cash, cash equivalents and short-term investments, fair value	48,699	42,886
Commercial paper		18,097
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Short-term investment, amortized Cost	25,913	9,794
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	25,913	9,794
Short-term Corporate Debt [Member]
Short-term investment, amortized Cost	9,515
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Short-term investment, fair value	9,515
US Government Agencies Short-term Debt Securities [Member]
Short-term investment, amortized Cost		5,818
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Short-term investment, fair value		5,818
Cash [Member]
Cash and cash equivalent, fair value	2,984	5,181
Money Market Funds [Member]
Cash and cash equivalent, fair value	$ 10,287	3,996
Commercial Paper [Member]
Cash and cash equivalent, fair value		$ 18,097
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 2 - Investments and Fair_5

Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets, fair value	$ 45,715	$ 37,705
Liabilities, fair value	109	246
Contingent Put Option Liability [Member]
Liabilities, fair value	109	246
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	10,287	3,996
Liabilities, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	35,428	33,709
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Liabilities, fair value	109	246
Fair Value, Inputs, Level 3 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	109	246
Money Market Funds [Member]
Assets, fair value	10,287	3,996
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	10,287	3,996
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Commercial Paper [Member]
Assets, fair value	25,913	27,891
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	25,913	27,891
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
U.S. Government Agency Securities [Member]
Assets, fair value		5,818
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value		0
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		5,818
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value		$ 0
Corporate Debt Securities [Member]
Assets, fair value	9,515
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	9,515
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	$ 0

Note 2 - Investments and Fair_6

Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Fair value, Beginning of period	$ 128	$ 591	$ 246	$ 437
Change in fair value of contingent put option associated with the Loan Agreement	(19)		(137)
Change in fair value of contingent put option associated with the Loan Agreement		(85)		69
Fair value, End of period	$ 109	$ 506	$ 109	$ 506

Note 3 - Inventories, Net (Deta

Note 3 - Inventories, Net (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
ZALVISO [Member]
Inventory Write-down	$ 0.1	$ 0.2	$ 0.2	$ 0.6
Amended License Agreement [Member]
Inventory Write-down				0.3
DSUVIA [Member]
Inventory Write-down				$ 0.3

Note 3 - Inventories, Net - Inv

Note 3 - Inventories, Net - Inventory Components (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Raw materials	$ 579	$ 257
Work-in-process	68	30
Finished goods	909	1,339
Total	$ 1,556	$ 1,626	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 4 - Revenue From Contrac_3

Note 4 - Revenue From Contracts With Customers (Details Textual) $ in Thousands, € in Millions	Jul. 14, 2021	Jul. 31, 2021	Sep. 30, 2021USD ($)	Sep. 30, 2021EUR (€)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Revenue from Contract with Customer, Including Assessed Tax			$ 1,862		$ 1,368	$ 2,816	$ 4,678
Contract with Customer, Liability, Total			1,237			1,237		$ 49
DZUVEO [Member]
Contract with Customer, Liability, Total			1,237			1,237		$ 0
DZUVEO [Member] | Aguettant [Member]
Proceeds form Up-front and Sales-based Milestone License Payments			2,900	€ 2.5
License Agreement, Milestone Payments and Revenue Share Payments to be Received			52,200			52,200
License Agreement, Term (Year)	10 years	10 years
License Agreement, Renewal Term (Year)	5 years	5 years
Revenue from Contract with Customer, Including Assessed Tax			1,700
Contract with Customer, Liability, Total			1,200			1,200
Capitalized Contract Cost, Amortization			$ 300			$ 300

Note 4 - Revenue From Contrac_4

Note 4 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 1,862	$ 1,368	$ 2,816	$ 4,678
DSUVIA [Member]
Revenue	160	935	733	1,092
ZALVISO [Member]
Revenue	0	352	270	772
Product [Member]
Revenue	160	1,287	1,003	1,864
License [Member]
Revenue	1,696		1,696
Non-cash Royalty [Member]
Revenue	0	60	83	181
Royalty [Member]
Revenue	0	21	28	61
Contract and Other Revenue [Member]
Revenue	6	0	6	2,572
Contract and Other Collaboration [Member]
Revenue	$ 1,702	$ 81	$ 1,813	$ 2,814

Note 4 - Revenue From Contrac_5

Note 4 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Contract Liabilities: Deferred Revenue			$ 49
Contract Liabilities: Deferred Revenue, Additions			1,237
Contract Liabilities: Deferred Revenue, Deductions			(49)
Contract Liabilities: Deferred Revenue	$ 1,237		1,237
Revenue	1,862	$ 1,368	2,816	$ 4,678
DZUVEO [Member]
Contract Liabilities: Deferred Revenue			0
Contract Liabilities: Deferred Revenue, Additions			1,237
Contract Liabilities: Deferred Revenue, Deductions			0
Contract Liabilities: Deferred Revenue	1,237		1,237
Amended License Agreement [Member]
Contract Liabilities: Deferred Revenue			49
Contract Liabilities: Deferred Revenue, Additions			0
Contract Liabilities: Deferred Revenue, Deductions			(49)
Contract Liabilities: Deferred Revenue	0		0
Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied	0	147	49	380
Performance obligations eliminated upon termination	0	0	0	2,572
Performance obligations satisfied at a point in time	1,696	205	1,917	392
Revenue	$ 1,696	$ 352	$ 1,966	$ 3,344

Note 5 - Long-term Debt (Detail

Note 5 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 01, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	May 30, 2019
Amortization of Debt Discount (Premium)				$ 607	$ 823
Leasehold Improvements, Gross		$ 1,700		1,700
Site Readiness Agreement [Member]
Debt Instrument, Periodic Payment, Principal	$ 500
Total Obligation Under Leasehold Agreement		$ 400		$ 400		$ 800
Debt Instrument, Interest Rate, Effective Percentage		14.35%		14.35%
Warrant In Connection with Oxford Finance Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							176,679
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 2.83
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Face Amount							$ 25,000
Long-term Debt, Total		$ 15,300		$ 15,300		$ 21,000
Interest Expense, Debt, Total		500	$ 700	1,700	2,400
Amortization of Debt Discount (Premium)		$ 100	$ 200	$ 500	$ 700

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual)	Mar. 26, 2021USD ($)	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Dec. 31, 2022USD ($)	Apr. 30, 2021USD ($)	Apr. 21, 2021	Dec. 31, 2020USD ($)	[1]
Gain (Loss) on Termination of Lease	$ 500,000	$ 0	$ 0	$ 522,000	$ 0
Operating Lease, Right-of-Use Asset		$ 4,454,000		$ 4,454,000					$ 3,150,000
Catalent Pharma Solutions [Member]
Lessee, Operating Lease, Term of Contract (Year)								5 years
Lessee, Operating Lease, Renewal Term (Year)								2 years
Catalent Pharma Solutions [Member] | Forecast [Member]
Operating Lease, Expense						$ 1,000,000
Prepaid Expenses and Other Current Assets [Member]
Lessee, Operating Sublease, Deferred Costs							$ 300,000
Lease for Corporate Headquarters in Hayward, California [Member]
Area of Real Estate Property (Square Foot) | ft²		12,106		12,106
Lessee, Operating Lease, Term of Contract (Year)	2 years 3 months
Lessee, Operating Lease, Monthly Rent	$ 17,000
Lessee, Operating Lease, Abated Rent Period (Month)	1 month
Operating Lease, Right-of-Use Asset	$ 400,000
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 6 - Leases - Operating Lea

Note 6 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	Mar. 26, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating lease costs		$ 343	$ 305	$ 1,123	$ 914
Gain on derecognition of operating lease	$ (500)	0	0	(522)	0
Sublease income		0	(150)	(199)	(449)
Loss on termination of sublease		0	0	331	0
Net lease costs		$ 343	$ 155	$ 733	$ 465
Weighted-average remaining term – operating lease (years) (Year)		5 years 2 months 15 days		5 years 2 months 15 days
Weighted-average discount rate – operating lease		12.80%		12.80%

Note 6 - Leases - Maturities of

Note 6 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	[1]
2021 (remaining three months)	$ 237
2022	1,483
2023	1,194
2024	1,040
2025	1,040
2026	1,040
Thereafter	415
Total future minimum lease payments	6,449
Less imputed interest	(1,785)
Total	4,664
Operating lease liabilities	4,664
Operating lease liabilities, current portion	(729)	$ (1,118)
Operating lease liabilities, net of current portion	$ 3,935	$ 2,606
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 7 - Liability Related to_3

Note 7 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Millions	Sep. 18, 2015	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Proceeds From Sale of Royalty and Milestone Rights	$ 65
Royalty Arrangment Maximum Payments	$ 195
Contingent Gain (Loss) on Royalty Monetization Arrangement				$ 64
Effective Interest Over Life of Liability Related to Sale of Future Royalties				0.00%
Effective Annual Interest Rate		3.50%	3.60%	3.50%	3.60%
SWK [Member]
Percentage of Royalties and Rights Under Agreement	75.00%
SWK [Member] | First Four Commercial Milestones [Member]
Percentage of Royalties and Rights Under Agreement	80.00%
Commercial Milestones Value Maximum Amount Available	$ 35.6
AcelRX [Member] | First Four Commercial Milestones [Member]
Commercial Milestones Value Maximum Amount Available	$ 44.5

Note 7 - Liability Related to_4

Note 7 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		72 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021
Liability related to sale of future royalties — beginning balance			$ 88,471		$ 0
Proceeds from sale of future royalties			0		61,184
Non-cash royalty revenue			(145)		(1,083)
Non-cash interest (income) expense recognized	$ (764)	$ (825)	(2,345)	$ (2,502)	25,880
Liability related to sale of future royalties as of September 30, 2021	$ 85,981		$ 85,981		$ 85,981

Note 8 - Legal Proceedings (Det

Note 8 - Legal Proceedings (Details Textual)	Jul. 06, 2021	Jun. 08, 2021
Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]
Loss Contingency, Number of Defendants		2
Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]
Loss Contingency, Number of Defendants	10

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jun. 17, 2021	Jan. 27, 2021	Jan. 27, 2021	Jan. 22, 2021	May 09, 2019	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 16, 2020
Proceeds from Issuance of Common Stock							$ 36,360	$ 11,400
The 2020 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	4,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)									5,500,000
The 2020 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	4,300,000
Private Placement [Member] | Armistice Capital and Rock Springs Capital [Member]
Stock Issued During Period, Shares, New Issues (in shares)		2,175,000	16,675,000	14,500,000
Shares Issued, Price Per Share (in dollars per share)		$ 1.7625	$ 1.7625	$ 1.7625
Proceeds from Issuance of Common Stock			$ 28,900
ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						0	3,000,000	876,800
Proceeds from Issuance of Common Stock							$ 7,500	$ 1,500
Aggregate Offering Price, Maximum					$ 80,000		$ 36,100

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation (Details Textual) - The 2020 Equity Incentive Plan [Member]	Sep. 30, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	12,170,713
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	14,376,874
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	1,828,448

Note 10 - Stock-based Compens_4

Note 10 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock-based compensation expense	$ 1,221	$ 1,104	$ 3,482	$ 3,340
Cost of Sales [Member]
Stock-based compensation expense	24	25	67	98
Research and Development Expense [Member]
Stock-based compensation expense	216	188	597	572
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 981	$ 891	$ 2,818	$ 2,670

Note 11 - Net Loss Per Share _3

Note 11 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
RSU's, ESPP, and Employee Stock Options [Member]
Antidilutive securities (in shares)	16,475,322	14,669,512
Warrant [Member]
Antidilutive securities (in shares)	176,679	176,679

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Lowell Therapeutics [Member] $ in Millions	Nov. 14, 2021USD ($)
Business Combination, Consideration Transferred, Net of Cash Acquired	$ 32.5
Business Combination, Contingent Consideration, Liability, Total	26
Contingent Consideration Payable if Cash Requirement is Met [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	6.5
Business Combination, Contingent Consideration Arrangements, Cash Requirement	3.5
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	$ 3.5